<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923403</url>
  </required_header>
  <id_info>
    <org_study_id>555-210</org_study_id>
    <nct_id>NCT00923403</nct_id>
  </id_info>
  <brief_title>Efficacy of Sterol-Fortified Low Fat Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans - Study II</brief_title>
  <official_title>Efficacy of Sterol-Fortified Low Fat Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans - Study II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WhiteWave Foods, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypercholesterolemia is a well-established risk factor for the development of&#xD;
      atherosclerosis, a component of cardiovascular disease (CVD). The National Cholesterol&#xD;
      Education Program advises the public to consume 2 g/day of plant sterols or stanols in&#xD;
      addition to the Therapeutic Lifestyle Change Diet to lower elevated low-density lipoprotein&#xD;
      (LDL) cholesterol levels. For foods to carry the FDA health claim label they must contain&#xD;
      0.65 g of phytosterol ester or 1.7 g of phytostanol ester per serving. The study was a&#xD;
      controlled diet, cross-over clinical investigation using a Latin square sequence. It&#xD;
      consisted of two 29 d phases separated by a four week wash out interval. Subjects were&#xD;
      randomized to one of two treatment arms: 1 % dairy milk or low-fat soy beverage providing&#xD;
      1.95 g plant sterols/day.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma cholesterol</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control dairy milk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>plant sterol enriched soymilk</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>plant sterol enriched soymilk</intervention_name>
    <description>plant sterol enriched soymilk</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>control dairy milk</intervention_name>
    <description>control dairy milk</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females, age 19-60 years old, will be screened for determination of&#xD;
             fasting circulating LDL-cholesterol and triglyceride (TG) levels.&#xD;
&#xD;
          2. Subjects accepted into the study will have plasma LDL-C levels between 120 and 200&#xD;
             mg/dl, TG levels below 250 mg/dl, and a body mass index (BMI) between 22 to 32 kg/m2.&#xD;
&#xD;
          3. Subjects must also demonstrate an ability to understand dietary and exercise&#xD;
             procedures and be judged as compliant and motivated by the investigators.&#xD;
&#xD;
          4. Subjects will be permitted to take stable doses of thyroid hormone and&#xD;
             anti-hypertensive agents, as long as these are continued equivalently throughout the&#xD;
             duration of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of recent (i.e. less than 3 mo) or chronic use of oral hypolipidemic therapy,&#xD;
             including fish oils, or probucol within the last 6 months.&#xD;
&#xD;
          2. History of chronic use of alcohol (&gt;2 drinks/d), systemic antibodies, corticosteroids,&#xD;
             androgens, or phenytoin.&#xD;
&#xD;
          3. Myocardial infarction, coronary artery bypass, or other major surgical procedures&#xD;
             within the last six months.&#xD;
&#xD;
          4. Recent onset of angina, congestive heart failure, inflammatory bowel disease,&#xD;
             pancreatitis, diabetes, or significant current (ie. onset within past three months)&#xD;
             gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of&#xD;
             active lesions, chemotherapy or surgery in the past year).&#xD;
&#xD;
          5. Exercise greater than walking or running 15 miles/wk or 4,000 kcal/week.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter JH Jones, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richardson Centre for Functional Foods and Nutraceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richardson Centre for Functional Foods and Nutraceuticals</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 6C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <last_update_submitted>June 17, 2009</last_update_submitted>
  <last_update_submitted_qc>June 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Peter JH Jones</name_title>
    <organization>Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba</organization>
  </responsible_party>
  <keyword>plant sterols</keyword>
  <keyword>diet</keyword>
  <keyword>soymilk</keyword>
  <keyword>cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

